The combinatory therapy of immunostimulatory cytokines IL-1β, IL-18, or IL-12 with GSDMD-based pyroptosis while not causing systemic adverse effects generates a robust antitumor response, ultimately leading to long-term remission in mouse melanoma model. Here, IL1B is linked to melanoma.